Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pregabalin placebo Clear all
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia

NCT00599638
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
pregabalin, pregabalin/PF-00489791, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
39
States / cities
Huntsville, Alabama • Tallassee, Alabama • Chandler, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.

NCT02277548
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma to the Head and Neck
Interventions
Lyrica 300 mg, Placebo
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 28, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

NCT02372578
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
ASP3662, pregabalin, ASP3662 placebo, pregabalin placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
37
States / cities
Anniston, Alabama • Phoenix, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 28, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

NCT00696787
View directory record Official record
Conditions
Fibromyalgia
Interventions
Desvenlafaxine Sustained Release (DVS SR), Lyrica® (Pregabalin), Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Huntsville, Alabama • Roseville, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel

NCT01637077
View directory record Official record
Conditions
Pain, Peripheral Neuropathy
Interventions
pregabalin, placebo, questionnaire administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Wichita, Kansas • Duluth, Minnesota • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 28, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional

[S,S]-Reboxetine Add-On Trial

NCT00334685
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine + Pregabalin, Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Huntsville, Alabama • Gilbert, Arizona • North Dartmouth, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

NCT02215252
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PharmacofMRI of Anxiolytic Medications (Pregabalin)

NCT00706836
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Pregabalin 50mg, Pregabalin 200 MG, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 28, 2026, 2:14 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae

NCT03031340
View directory record Official record
Conditions
Spinal Fusion
Interventions
Pregabalin, placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 28, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

NCT05995535
View directory record Official record
Conditions
Opiate Withdrawal Syndrome, Opioid Use
Interventions
LFX/PGB, LFX/PLA-PGB
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

NCT01701362
View directory record Official record
Conditions
Neuropathic Pain
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
105
States / cities
Huntsville, Alabama • Goodyear, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

NCT01455415
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Once-A-Day Pregabalin For Partial Seizures

NCT01262677
View directory record Official record
Conditions
Partial Seizures, Epilepsies, Partial
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Terminated Phase 3 Interventional Results available

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217
View directory record Official record
Conditions
Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Early Phase 1 Interventional Results available

Behavioral Effects of Pregabalin and Cannabis

NCT01511640
View directory record Official record
Conditions
Cannabis-use Disorders
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

Preoperative Pain Control in Gastric Bypass Surgery Patients

NCT01801189
View directory record Official record
Conditions
Post-operative Pain
Interventions
Pregabalin, Placebo (for Pregabalin)
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 28, 2026, 2:14 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

Pregabalin for the Treatment of Vulvodynia

NCT00853229
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis
Interventions
pregabalin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-639, pregabalin, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

NCT04495283
View directory record Official record
Conditions
Postoperative Pain
Interventions
Pregabalin, Acetaminophen, Placebo 1, Placebo 2
Drug · Other
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Pasadena, California • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

NCT00468845
View directory record Official record
Conditions
Pain, Postoperative
Interventions
pregabalin (Lyrica), matched placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
25 Years to 70 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

NCT00977197
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 28, 2026, 2:14 PM EDT